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ABSTRACT 
 
Background: It is unclear if haemodiafiltration improves patient survival compared to 
standard haemodialysis. Observational studies have tended to show benefit with 
haemodiafiltration, while meta-analyses have not provided definitive proof of superiority. 
Methods: Using data from the ANZDATA Registry, this binational inception cohort study 
compared all adult patients who commenced haemodialysis in Australia and New Zealand 
between 2000 and 2014. The primary outcome was all-cause mortality. Cardiovascular 
mortality was the secondary outcome. Outcomes were measured from the first haemodialysis 
treatment and were examined using multivariable Cox regression analyses. Patients were 
censored at permanent discontinuation of haemodialysis or at 31 December 2014. Analyses 
were stratified by country. 
Results: The study included 26,961 patients (4,110 haemodiafiltration, 22,851 standard 
haemodialysis; 22,774 Australia, 4,187 New Zealand) with a median follow-up of 5.31 (IQR 
2.87-8.36) years. Median age was 62 years, 61% were male, 71% were Caucasian. Compared 
to standard haemodialysis, haemodiafiltration was associated with a significantly lower risk 
of all-cause mortality (adjusted HR for Australia 0.79, 95% CI 0.72-0.87; adjusted HR for 
New Zealand 0.88, 95% CI 0.78-1.00). In Australian patients, there was also an association 
between haemodiafiltration and reduced cardiovascular mortality (adjusted HR 0.78, 95% CI 
0.64-0.95). 
Conclusions: Haemodiafiltration was associated with superior survival across patient 
subgroups of age, sex and comorbidity. 
 
Keywords: dialysis; end stage renal disease; hemodiafiltration; hemodialysis; survival. 
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INTRODUCTION 
 
Despite gradual improvements in patient survival on haemodialysis, annual crude mortality 
rates remain high, ranging from 6.6% in Japan to 21.7% in the United States.1,2 While 
increasing patient age and comorbidity burden are key contributors to the heightened risk of 
death, the cardiovascular sequelae of intradialytic haemodynamic instability and uraemic 
toxin accumulation may also play a role.3–5 
 
Through mitigation of intradialytic hypotension and enhanced removal of medium and large 
uraemic toxins, it has been hypothesised that use of haemodiafiltration may confer a survival 
benefit compared to standard haemodialysis. Several observational studies have supported an 
association between haemodiafiltration and reduced all-cause and cardiovascular mortality,6–
13 although a recent analysis using data from European countries participating in the Dialysis 
Outcomes and Practice Patterns Study did not detect a survival difference between 
modalities.14 Four meta-analyses15–18 have not conclusively supported the superiority of 
haemodiafiltration. The most consistent finding has been that of an association between high 
convection volume haemodiafiltration and superior survival, from secondary, post-hoc, and 
pooled individual patient data analyses of the randomised trials.13,19–22 Although encouraging, 
such analyses can only be interpreted as observational, since convection volume was not 
randomised within the studies. 
 
Existing observational studies have been limited by single centre design, small patient 
numbers, inclusion of prevalent haemodialysis patients, or variable haemodiafiltration 
practices. Randomised trials have been weakened by flawed methodology, failure to achieve 
or adequately dose convection volume, and insufficient duration and completeness of follow 
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up. No large study has compared haemodiafiltration and standard haemodialysis outside 
Europe, and regional practice pattern variation may be significant.23 In light of these 
limitations, this study used a population-based approach to compare patient survival on 
haemodiafiltration and standard haemodialysis in Australia and New Zealand over a 15 year 
period. 
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METHODS 
 
Study design 
 
This was an inception cohort study using patient records from the Australia and New Zealand 
Dialysis and Transplant (ANZDATA) Registry. The ANZDATA Registry collects data 
annually from all units throughout Australia and New Zealand for all people receiving 
chronic renal replacement therapy. Details of the ANZDATA Registry have been previously 
described.24 
 
Study population 
 
All adult patients (≥ 18 years) who commenced standard haemodialysis or haemodiafiltration 
in Australia or New Zealand between 1 January 2000 and 31 December 2014 were included 
in the study, including those who had previously received peritoneal dialysis or a renal 
transplant. Patients were censored at the time of permanent discontinuation of haemodialysis 
(i.e. transfer to peritoneal dialysis, renal transplantation, recovery of renal function, or loss to 
follow up) or at 31 December 2014. Patients who temporarily discontinued haemodialysis 
(i.e. renal transplantation or peritoneal dialysis with return to haemodialysis) were removed 
from the risk set but were re-included from the time they re-initiated haemodialysis. 
 
Data collection 
 
ANZDATA records were used for patient demographics (age, sex, race, country), 
comorbidities (body mass index, chronic lung disease, coronary artery disease, 
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cerebrovascular disease, peripheral vascular disease, diabetes mellitus, smoking status), and 
dialysis prescription at the commencement of haemodialysis (vascular access type, blood 
flow rate, treatment time, setting [home, hospital, satellite], erythropoietin use). The initial 
mode of haemodialysis was determined at 90 days after the first treatment. The 
haemodiafiltration group included all patients who received at least one haemodiafiltration 
treatment during the study period. The ANZDATA Registry updates haemodialysis modality 
(haemodiafiltration or haemodialysis) and prescription (treatment time, blood flow rate, 
vascular access) annually; changes in renal replacement therapy modality (haemodialysis, 
peritoneal dialysis or transplant) and setting (hospital, satellite, or home) are updated in real 
time. 
 
Derived indices included Socio-Economic Indexes For Areas (SEIFA), 
Accessibility/Remoteness Index of Australia Plus (ARIA+) scores, and estimated 
haemodiafiltration convection volume. SEIFA and ARIA+ scores were developed by the 
Australian Bureau of Statistics and use postcodes to estimate socioeconomic status and 
residential remoteness. A SEIFA score in the highest decile was considered advantaged, 
whereas a score in the lowest decile was used to describe socioeconomic disadvantage. 
ARIA+ categories were recorded as 0 to <1 major city, 1 to <3 regional, 3 to 4 remote. 
SEIFA and ARIA scores were calculable for Australian patients only. There is no equivalent 
measure calculable for New Zealand patients. Estimates of minimum delivered 
haemodiafiltration convection volume were derived by multiplying blood flow rate, dialysis 
hours, and a minimum filtration fraction of 0.20, assuming postdilution haemodiafiltration 
mode. 
 
Clinical outcomes 
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The primary outcome was all-cause mortality, measured as the time from the first 
haemodialysis treatment to death. Cause-specific mortality was estimated using cause of 
death reported to ANZDATA. Time to cardiovascular death (i.e. death due to myocardial 
ischaemia, cardiac failure, cardiac arrest, pulmonary oedema, or hyperkalaemia) was a 
secondary outcome. 
 
Statistical analyses 
 
All data were analysed using STATA software package (version 14.0, College Station, TX: 
StataCorp LP, USA). All reporting was performed in accordance with the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines.25 
 
Baseline characteristics were expressed as patient numbers (n, %), means (± standard 
deviation), or medians (interquartile range, IQR), as appropriate. Univariable and 
multivariable Cox regression models were used to examine the primary outcome, overall 
mortality. Because the ANZDATA Registry records modality changes, haemodialysis 
modality was treated as a time-varying covariate, where patients could switch from one 
modality to the other. Multivariable models included all variables with a univariable p-value 
less than 0.25. Interaction terms between haemodiafiltration and pre-specified variables (age, 
sex, race, body mass index, and year of haemodialysis start) were examined. Backwards 
elimination was used to exclude variables or interaction terms that were not confounders (a 
confounder was defined as >10% change in hazard ratio [HR] for haemodiafiltration), or 
those that were not statistically significant. Statistically significant was defined as a p-value 
<0.05 for main effects and p <0.01 for effect modifiers. Standard errors were  adjusted for the 
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clustering of observations within treatment centres using the sandwich estimator.26 To ensure 
comparability between the Australian and New Zealand analyses, all variables remaining in 
either the Australian or New Zealand models were included in the final multivariable models. 
Modelled survival curves were generated for each country. To test for any cumulative effect 
of haemodiafiltration, a categorical variable was included in the final model, which estimated 
the effect of haemodiafiltration treatment for the first year and the effect for more than one 
year. 
 
Cause-specific Cox regression models were used to examine the association between 
haemodiafiltration and cardiovascular mortality, and between haemodiafiltration and non-
cardiovascular mortality. Competing risk analysis was considered inappropriate given the 
presence of time-varying covariates, since the Fine and Gray model “prohibits the 
introduction of any time-dependent covariate in the model when death is a competing cause 
of failure”.27 Variables included in the multivariable models were the same as the primary 
analysis. Pre-specified sub-group analyses were conducted for all-cause and cardiovascular 
mortality. Subgroups of interest included age, sex, diabetes, obesity, cardiovascular disease, 
and vascular access subtype.  
 
A sensitivity analysis excluding centres which did not practice haemodiafiltration was also 
performed, as well as a sensitivity analysis adjusting for the clustering of observations within 
treatment centres using random effects. Proportional hazards assumptions were tested 
graphically and using Schoenfeld residuals. Overall fit of each model was assessed using 
Cox-Snell residuals.28 Individuals with missing data for any variable in the adjusted models 
were excluded; no imputation was performed for missing data.   
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RESULTS 
 
Study population 
 
Between 1 January 2000 and 31 December 2014, 27,701 patients commenced haemodialysis 
in Australia and New Zealand (Figure 1). Of these, 269 patients were excluded due to 
missing haemodialysis modality data and 472 patients were excluded due to missing data 
pertaining to one or more covariates in the adjusted models. A total of 26,961 patients were 
included in the final analysis (22,774 from Australia and 4,187 from New Zealand), of whom 
4,110 underwent at least one treatment with haemodiafiltration (3,302 from Australia, 808 
from New Zealand). Baseline characteristics of the study population are described in Table 1. 
Country was a significant effect modifier of provision of haemodiafiltration; therefore, 
stratified analyses were conducted for Australia and New Zealand. 
 
There were 4,110 patients who ever received haemodiafiltration, of whom 1,014 (25%) 
started haemodialysis with haemodiafiltration, and 3,096 (75%) switched from standard 
haemodialysis to haemodiafiltration after a median of 2.69 (IQR 1.50 – 4.56) years. There 
were 2,447 (60%) patients who permanently remained on haemodiafiltration after starting or 
switching, and of the 1,663 (40%) patients who did switch off haemodiafiltration, 465 (28%) 
eventually returned. Median follow up was 5.31 (IQR 2.87-8.36) years overall, and 3.57 (IQR 
1.52-6.16) years on haemodialysis. 
 
The final multivariable models were adjusted for age, sex, race, body mass index, year of 
haemodialysis start, chronic lung disease, coronary artery disease, cerebrovascular disease, 
peripheral vascular disease, diabetes, smoking status, vascular access type, previous 
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transplant, initial treatment with haemodialysis, blood flow rate, weekly treatment time, and 
dialysis setting. There were no significant interactions between variables.  
 
Compared to patients who received standard haemodialysis, those receiving 
haemodiafiltration were more likely to be obese or diabetic, and were less likely to be 
Caucasian, aged ≥ 70 years, or to dialyse at home. Haemodiafiltration patients were less 
likely to have received a previous kidney transplant, but were more likely to have undergone 
prior renal replacement therapy. There was no difference in the proportion of patients with 
pre-existing cardiovascular disease or use of permanent vascular access between groups. 
 
Dialysis characteristics were assessed after 12 months of stabilisation on either 
haemodiafiltration or standard haemodialysis (Table 2). Compared to patients receiving 
standard haemodialysis, a greater proportion of haemodiafiltration patients had a blood flow 
rate ≥350ml/min and used a high flux dialyser. A smaller proportion of haemodiafiltration 
patients performed quotidian (3.5+ sessions per week) or extended hour (>5 hours per 
session) dialysis, and fewer required erythropoietin. Vascular access and phosphate control 
were comparable between cohorts at 12 months. 
 
All-cause mortality 
 
There were 11,503 deaths during the study period (753 in the haemodiafiltration group, 
10,750 in the standard haemodialysis group). The crude mortality rate was lower in patients 
who received haemodiafiltration compared to those managed with standard haemodialysis 
(8.87 vs 14.95 deaths per 100 patient-years). Crude median survival for patients on 
haemodiafiltration was 6.30 (IQR 3.26-11.42) years, compared to 6.26 (IQR 2.92-not 
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reached) years for patients who received standard haemodialysis. In the multivariable model, 
haemodiafiltration was independently associated with a significantly lower risk of death 
across both countries (HR for Australia 0.79, 95% CI 0.72-0.87, p < 0.001; HR for New 
Zealand 0.88, 95% CI 0.78-1.00, p =0.05) (Table 3, Figures 2-3). There was evidence of a 
decreasing beneficial effect of haemodiafiltration over time for patients in New Zealand (p 
<0.001) (Table 4). A similar pattern was observed for Australia, but there was insufficient 
evidence to conclude that the benefits of haemodiafiltration changed over time (p =0.09). 
 
Cardiovascular mortality 
 
A total of 3,957 patients died from cardiovascular causes (269 in the haemodiafiltration 
group, 3,688 in the standard haemodialysis group). The risk of cardiovascular death was 
lower in patients receiving haemodiafiltration in Australia (HR 0.78, 95% CI 0.64-0.95, p = 
0.01), but not in New Zealand (HR 1.09, 95% CI 0.85-1.41, p=0.48), compared to patients 
managed with standard haemodialysis (Figure 3). 
 
The cause-specific survival curves for cardiovascular and non-cardiovascular causes of death 
are presented in Figure 4. In both countries, haemodiafiltration was associated with a lower 
risk of non-cardiovascular death compared to standard haemodialysis. Haemodiafiltration 
was also associated with a reduced risk of cardiovascular death in Australian patients, but 
there was no evidence of any haemodiafiltration effect for cardiovascular death in New 
Zealand patients. 
 
Subgroup analyses 
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There was no significant interaction between all-cause mortality and any patient subgroup in 
Australian patients (Figure 5). In New Zealand patients, haemodiafiltration was associated 
with a greater reduction in all-cause mortality in patients aged <65 years (HR 0.76, 95% CI 
0.63-0.91), compared to those aged ≥65 years (HR 1.04, 95% CI 0.89-1.22; p-value for 
interaction 0.004)., and in diabetic patients (HR 0.84, 95% CI 0.70-1.01) more so than non-
diabetic patients (HR 0.94, 95% CI 0.85-1.03; p-value for interaction <0.001). 
 
There was no significant interaction between cardiovascular mortality and any patient 
subgroup in Australian patients (Figure 6). In New Zealand patients, haemodiafiltration was 
associated with an increased risk of cardiovascular mortality in patients aged ≥65 years (HR 
1.56, 95% CI 1.23-1.99) compared to those aged <65 years (HR 0.88, 95% CI 0.63-1.22; p-
value for interaction <0.001), and in non-diabetic patients (HR 1.45, 95% CI 1.19-1.78) 
compared to diabetic patients (HR 0.96, 95% CI 0.72-1.27; p-value for interaction <0.001). 
 
Sensitivity analyses 
 
When patients managed by centres which did not practice haemodiafiltration were excluded 
from the analysis, the association between haemodiafiltration and reduced all-cause mortality 
remained significant for both Australian (HR 0.79, 95% CI 0.72-0.87) and New Zealand (HR 
0.88, 95% CI 0.78-1.00) patients. Similarly, there was an association between 
haemodiafiltration and reduced cardiovascular mortality in Australian patients (HR 0.78, 
95% CI 0.64-0.95), but not in New Zealand patients (HR 1.09, 95% CI 0.85-1.41). There 
were no differences in outcome when clustering of observations within treatment centres was 
adjusted for as a random effect. 
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DISCUSSION 
 
In this large, population-based cohort of patients from Australia and New Zealand who were 
followed for greater than 5 years, haemodiafiltration was associated with a significantly 
decreased risk of all-cause mortality compared to standard haemodialysis, even after 
adjustment for multiple potential confounders. In Australian patients, there was also an 
association between haemodiafiltration and reduced cardiovascular mortality, which was not 
demonstrated in patients from New Zealand. The beneficial effect of haemodiafiltration on 
survival was demonstrated across patient subgroups of age, sex, and comorbidity, and 
remained significant after exclusion of non-haemodiafiltration centres. 
 
The findings of this study are in keeping with the existing observational data6–12 and meta-
analyses by Mostovaya et al15 and Peters et al,,22 which reported an association between 
haemodiafiltration and decreased risks of all-cause and cardiovascular mortality compared to 
standard haemodialysis. However, superiority of haemodiafiltration was not confirmed by 
three other meta-analyses.16–18 Nistor et al compared convective therapies 
(haemodiafiltration, haemofiltration, acetate-free biofiltration) to standard haemodialysis, and 
found no difference in all-cause mortality between groups.16 They did report a reduction in 
the risk of cardiovascular mortality, which was also demonstrated by Susantitaphong et al 
when they compared convective therapies (high flux haemodialysis, haemofiltration or 
haemodiafiltration) to low flux haemodialysis.18 No survival benefit or reduction in 
cardiovascular events was found in a meta-analysis by Wang et al, who compared 
haemodiafiltration or haemofiltration to standard haemodialysis.17  
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Inconsistency between meta-analyses may be the result of differences in study inclusion 
criteria or the definition of convective dialysis. Importantly, their findings must be interpreted 
within the limitations of their constituent studies, some of which have been criticised for 
being of low quality and inadequate statistical power, and high risk of bias. In contrast to the 
present study, the completeness and duration of patient follow-up in many of the randomised 
trials may have been insufficient to detect a difference in outcome between the groups, and 
other aspects of their methodology may have introduced bias, especially attrition bias and 
selective outcome reporting bias. On the other hand, the potential for residual confounding or 
selection bias could not be excluded from the present study, despite the use of adjusted 
models. 
 
There are biologically plausible reasons why haemodiafiltration may confer a survival benefit 
compared to standard haemodialysis. Firstly, retention of uraemic toxins has been linked with 
accelerated atherosclerosis, which increases the risk of death.3–5 Augmented removal of 
middle and large-sized molecules by haemodiafiltration may reduce the burden of 
cardiovascular disease.29,30 Secondly, haemodiafiltration has been associated with enhanced 
intradialytic haemodynamic stability, potentially mediated by cooling of the extracorporeal 
circuit. This could protect against the development of dialysis-induced cardiac damage,21,31 
although one small randomised trial examining the intradialytic cardiac changes of 
haemodiafiltration did not demonstrate a reduction in regional wall motion abnormalities 
compared to standard haemodialysis.32 Finally, the use of ultrapure dialysis fluid and high 
flux synthetic membranes allows optimal biocompatibility of the system, which is thought to 
reduce systemic inflammation and oxidative stress.33–35 
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The difference in the risk of cardiovascular death between Australia and New Zealand is 
noteworthy. Whether this finding relates to a lower number of individuals exposed to 
haemodiafiltration and/or to a lower number of cardiovascular death events remains 
uncertain. Differences in the patient population (e.g. age and proportion of patients with 
ischaemic heart disease) and dialysis practices (e.g. treatment time and dialysis setting) 
between the two countries may also have played a role. Alternatively, it may reflect residual 
confounding or cause of death coding bias. 
 
This binational inception cohort study complements the existing haemodiafiltration literature 
as the largest observational study to be performed outside Europe. Its strengths lie in the use 
of a population-based approach, comprehensive multivariable models, and extended duration 
and completeness of follow up. However, through use of population-based data, specific 
details of the dialysis prescription (including convection volume, dialysate prescription, 
substitution modality, substitution and dialysate flow rates, and ultrafiltration rate), residual 
renal function, blood pressure, volume control, middle molecule clearance, and inflammation 
and nutrition markers cannot be known, since they are not collected by the registry. 
Furthermore, data on haemodialysis modality were collected annually by the registry so the 
exact exposure time of haemodiafiltration cannot be determined. Although residual 
confounding and treatment modality selection bias could not be excluded, sensitivity analyses 
and a thorough analytic approach were employed to minimise the potential for bias. 
 
Although the results of this study are hypothesis generating, strong recommendations for or 
against the routine use of haemodiafiltration in clinical practice cannot be made. Similarly, 
while emerging data from post-hoc, secondary, and pooled individual participant data 
analyses of the randomised trials have supported a more consistent benefit in patients 
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receiving the highest convection volumes of haemodiafiltration,22,36,37 superiority of this 
approach has not been demonstrated in an adequately powered randomised trial.  
 
The theoretical benefit of haemodiafiltration must also be weighed against any potential risks 
of this modality, including the infusion of large volumes of ultrapure dialysate, or an 
unjustified cost to health services. The latter is a controversial issue, with the comparative 
cost of haemodiafiltration and high flux haemodialysis being dependent on the expense 
associated with disposable tubing sets, sterilising ultrafilters, and the requirement for 
augmented microbiological monitoring of water and dialysis fluid. Two prospective studies 
have reported that haemodiafiltration is either marginally more expensive or cheaper than 
high flux haemodialysis, depending on the choice of consumables, substitution modality, and 
need for additional water quality testing.38,39 However, in cost-effectiveness analyses, which 
considered the worth of improved survival and health related quality of life, 
haemodiafiltration was considered to be a cost-effective treatment compared to both low flux 
haemodialysis40 and high flux haemodialysis.41 
 
In summary, the findings of this study suggest that haemodiafiltration may confer a survival 
advantage compared to standard haemodialysis in Australian and New Zealand patients. This 
benefit was independent of other factors previously associated with mortality, including 
treatment time, vascular access, and comorbidity burden. However, in the absence of robust, 
high quality evidence demonstrating a consistent benefit with haemodiafiltration compared 
with standard haemodialysis, widespread uptake in clinical practice is not currently 
supported. While this study provides further evidence that haemodiafiltration may improve 
outcomes, exploration of the merit and cost-effectiveness of high convection volume 
haemodiafiltration warrants consideration in randomised trials.  
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39.  Oates T, Cross J, Davenport A. Cost comparison of online haemodiafiltration with 
high-flux haemodialysis. J Nephrol. 2012;25(2):192-197. 
40.  Lévesque R, Marcelli D, Cardinal H, et al. Cost-effectiveness analysis of high-
efficiency hemodiafiltration versus low-flux hemodialysis based on the Canadian arm 
of the CONTRAST study. Appl Health Econ Health Policy. 2015;13(6):647-659. 
41.  Ramponi F, Ronco C, Mason G, et al. Cost-effectiveness analysis of online 
hemodiafiltration versus high-flux hemodialysis. Clin Outcomes Res. 2016;8:531-540. 
  
24 
 
Table 1: Baseline characteristics of study cohort of 26 961 patients commencing haemodialysis between 1 January 2000 and 31 December 2014. 
  Australia New Zealand Overall 
  Never HDF Ever HDF Total Never HDF Ever HDF Total Never HDF Ever HDF Total 
Number 19 472 3302 22 774 3379 808 4187 22 851 4110 26 961 
Age, years 
18-39 1,864 (10) 373 (11) 2,237 (10) 436 (13) 92 (11) 528 (13) 2,300 (10) 465 (11) 2,765 (10) 
40-54 4,184 (21) 769 (23) 4,953 (22) 984 (29) 219 (27) 1,203 (29) 5,168 (23) 988 (24) 6,156 (23) 
55-69 6,580 (34) 1,225 (37) 7,805 (34) 1,414 (42) 327 (40) 1,741 (42) 7,994 (35) 1,552 (38) 9,546 (35) 
70+ 6,844 (35) 935 (28) 7,779 (34) 545 (16) 170 (21) 715 (17) 7,389 (32) 1,105 (27) 8,494 (32) 
Sex 
Female 7,584 (39) 1,234 (37) 8,818 (39) 1,260 (37) 339 (42) 1,599 (38) 8,844 (39) 1,573 (38) 10,417 (39) 
Male 11,888 (61) 2,068 (63) 13,956 (61) 2,119 (63) 469 (58) 2,588 (62) 14,007 (61) 2,537 (62) 16,544 (61) 
Race  
White 15,009 (77) 2,498 (76) 17,507 (77) 1,286 (38) 231 (29) 1,517 (36) 16,295 (71) 2,729 (66) 19,024 (71) 
ATSI 2,200 (11) 393 (12) 2,593 (11) 1 (<1)  (0) 1 (<1) 2,201 (10) 393 (10) 2,594 (10) 
MPI 479 (2) 140 (4) 619 (3) 1,883 (56) 495 (61) 2,378 (57) 2,362 (10) 635 (15) 2,997 (11) 
Asian or Indian 1,254 (6) 191 (6) 1,445 (6) 171 (5) 67 (8) 238 (6) 1,425 (6) 258 (6) 1,683 (6) 
Other 530 (3) 80 (2) 610 (3) 38 (1) 15 (2) 53 (1) 568 (2) 95 (2) 663 (2) 
BMI, kg/m2 
<18.5 651 (3) 66 (2) 717 (3) 51 (2) 9 (1) 60 (1) 702 (3) 75 (2) 777 (3) 
18.5-30 12,814 (66) 1,871 (57) 14,685 (64) 1,663 (49) 392 (49) 2,055 (49) 14,477 (63) 2,263 (55) 16,740 (62) 
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>30 6,007 (31) 1,365 (41) 7,372 (32) 1,665 (49) 407 (50) 2,072 (49) 7,672 (34) 1,772 (43) 9,444 (35) 
Year 
2000-2004 6,035 (31) 558 (17) 6,593 (29) 1,196 (35) 102 (13) 1,298 (31) 7,231 (32) 660 (16) 7,891 (29) 
2005-2009 7,146 (37) 1,279 (39) 8,425 (37) 1,169 (35) 318 (39) 1,487 (36) 8,315 (36) 1,597 (39) 9,912 (37) 
2010-2014 6,291 (32) 1,465 (44) 7,756 (34) 1,014 (30) 388 (48) 1,402 (33) 7,305 (32) 1,853 (45) 9,158 (34) 
Chronic lung disease 
No 16,242 (83) 2,772 (84) 19,014 (83) 2,842 (84) 648 (80) 3,490 (83) 19,084 (84) 3,420 (83) 22,504 (83) 
Yes 3,230 (17) 530 (16) 3,760 (17) 537 (16) 160 (20) 697 (17) 3,767 (16) 690 (17) 4,457 (17) 
Coronary artery disease 
No 11,108 (57) 1,940 (59) 13,048 (57) 2,229 (66) 498 (62) 2,727 (65) 13,337 (58) 2,438 (59) 15,775 (59) 
Yes 8,364 (43) 1,362 (41) 9,726 (43) 1,150 (34) 310 (38) 1,460 (35) 9,514 (42) 1,672 (41) 11,186 (41) 
Cerebrovascular disease 
No 16,346 (84) 2,830 (86) 19,176 (84) 2,955 (87) 703 (87) 3,658 (87) 19,301 (84) 3,533 (86) 22,834 (85) 
Yes 3,126 (16) 472 (14) 3,598 (16) 424 (13) 105 (13) 529 (13) 3,550 (16) 577 (14) 4,127 (15) 
Peripheral vascular disease 
No 14,059 (72) 2,478 (75) 16,537 (73) 2,729 (81) 599 (74) 3,328 (79) 16,788 (73) 3,077 (75) 19,865 (74) 
Yes 5,413 (28) 824 (25) 6,237 (27) 650 (19) 209 (26) 859 (21) 6,063 (27) 1,033 (25) 7,096 (26) 
Diabetes mellitus 
No 10,637 (55) 1,754 (53) 12,391 (54) 1,565 (46) 321 (40) 1,886 (45) 12,202 (53) 2,075 (50) 14,277 (53) 
Yes 8,835 (45) 1,548 (47) 10,383 (46) 1,814 (54) 487 (60) 2,301 (55) 10,649 (47) 2,035 (50) 12,684 (47) 
Smoking history 
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Never smoked 8,768 (45) 1,448 (44) 10,216 (45) 1,388 (41) 404 (50) 1,792 (43) 10,156 (44) 1,852 (45) 12,008 (45) 
Current/former  10,704 (55) 1,854 (56) 12,558 (55) 1,991 (59) 404 (50) 2,395 (57) 12,695 (56) 2,258 (55) 14,953 (55) 
SEIFA ranking (Australia) 
Lowest Decile 2,165 (11) 348 (11) 2,513 (11) - - - 2,165 (9) 348 (8) 2,513 (9) 
Middle Deciles 15,483 (80) 2,643 (80) 18,126 (80) - - - 15,483 (68) 2,643 (64) 18,126 (67) 
Highest Decile 1,734 (9) 303 (9) 2,037 (9) - - - 1,734 (8) 303 (7) 2,037 (8) 
Unclassified 81 (<1) 4 (<1) 85 (<1) - - - 81 (<1) 4 (<1) 85 (<1) 
Not reported 9 (<1) 4 (<1) 13 (<1) - - - 9 (<1) 4 (<1) 13 (<1) 
ARIA+ Category (Australia) 
Major City 13,020 (67) 2,133 (65) 15,153 (67) - - - 13,020 (57) 2,133 (52) 15,153 (56) 
Regional 4,796 (25) 967 (29) 5,763 (25) - - - 4,796 (21) 967 (24) 5,763 (21) 
Remote 692 (4) 168 (5) 860 (4) - - - 692 (3) 168 (4) 860 (3) 
Unclassified 955 (5) 30 (<1) 985 (4) - - - 955 (4) 30 (<1) 985 (4) 
Not reported 9 (<1) 4 (<1) 13 (<1) - - - 9 (<1) 4 (<1) 13 (<1) 
Vascular access at first HD 
Native 11,666 (60) 2,038 (62) 13,704 (60) 1,500 (44) 262 (32) 1,762 (42) 13,166 (58) 2,300 (56) 15,466 (57) 
Synthetic 1,022 (5) 176 (5) 1,198 (5) 95 (3) 22 (3) 117 (3) 1,117 (5) 198 (5) 1,315 (5) 
Tunneled CVC 5,921 (30) 964 (29) 6,885 (30) 1,391 (41) 423 (52) 1,814 (43) 7,312 (32) 1,387 (34) 8,699 (32) 
Temporary CVC 863 (4) 124 (4) 987 (4) 393 (12) 101 (13) 494 (12) 1,256 (5) 225 (5) 1,481 (5) 
Location at first HD 
Home 1,173 (6) 74 (2) 1,247 (5) 467 (14) 20 (2) 487 (12) 1,640 (7) 94 (2) 1,734 (6) 
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Hospital 8,355 (43) 1,370 (41) 9,725 (43) 2,053 (61) 590 (73) 2,643 (63) 10,408 (46) 1,960 (48) 12,368 (46) 
Satellite 8,645 (44) 1,551 (47) 10,196 (45) 551 (16) 71 (9) 622 (15) 9,196 (40) 1,622 (39) 10,818 (40) 
Not reported 1,299 (7) 307 (9) 1,606 (7) 308 (9) 127 (16) 435 (10) 1,607 (7) 434 (11) 2,041 (8) 
Previous transplant 
No 15,737 (81) 2,754 (83) 18,491 (81) 2,851 (84) 760 (94) 3,611 (86) 18,588 (81) 3,514 (85) 22,102 (82) 
Yes 3,735 (19) 548 (17) 4,283 (19) 528 (16) 48 (6) 576 (14) 4,263 (19) 596 (15) 4,859 (18) 
Previous EPO 
No 15,737 (81) 2,754 (83) 18,491 (81) 2,851 (84) 760 (94) 3,611 (86) 18,588 (81) 3,514 (85) 22,102 (82) 
Yes 3,735 (19) 548 (17) 4,283 (19) 528 (16) 48 (6) 576 (14) 4,263 (19) 596 (15) 4,859 (18) 
Blood flow rate 
< 250ml/min 1,853 (10) 218 (7) 2,071 (9) 478 (14) 69 (9) 547 (13) 2,331 (10) 287 (7) 2,618 (10) 
250-299ml/min 4,827 (25) 747 (23) 5,574 (24) 1,204 (36) 413 (51) 1,617 (39) 6,031 (26) 1,160 (28) 7,191 (27) 
300-349ml/min 10,216 (52) 1,816 (55) 12,032 (53) 1,346 (40) 291 (36) 1,637 (39) 11,562 (51) 2,107 (51) 13,669 (51) 
350+ ml/min 2,576 (13) 521 (16) 3,097 (14) 351 (10) 35 (4) 386 (9) 2,927 (13) 556 (14) 3,483 (13) 
Treatment time 
<12 hr/week 1,548 (8) 251 (8) 1,799 (8) 125 (4) 21 (3) 146 (3) 1,673 (7) 272 (7) 1,945 (7) 
12-12.9 hr/week 8,876 (46) 1,344 (41) 10,220 (45) 1,359 (40) 419 (52) 1,778 (42) 10,235 (45) 1,763 (43) 11,998 (45) 
13-13.9 hr/week 2,342 (12) 498 (15) 2,840 (12) 340 (10) 145 (18) 485 (12) 2,682 (12) 643 (16) 3,325 (12) 
14+ hr/week 4,473 (23) 766 (23) 5,239 (23) 1,069 (32) 93 (12) 1,162 (28) 5,542 (24) 859 (21) 6,401 (24) 
Not reported 2,233 (11) 443 (13) 2,676 (12) 486 (14) 130 (16) 616 (15) 2,719 (12) 573 (14) 3,292 (12) 
Cause of ESKD 
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Diabetes 6,598 (34) 1,184 (36) 7,782 (34) 1,587 (47) 437 (54) 2,024 (48) 8,185 (36) 1,621 (39) 9,806 (36) 
Glomerulonephritis 4,497 (23) 776 (24) 5,273 (23) 771 (23) 153 (19) 924 (22) 5,268 (23) 929 (23) 6,197 (23) 
Cystic disease 1,219 (6) 232 (7) 1,451 (6) 181 (5) 20 (2) 201 (5) 1,400 (6) 252 (6) 1,652 (6) 
Renovascular 2,849 (15) 458 (14) 3,307 (15) 322 (10) 83 (10) 405 (10) 3,171 (14) 541 (13) 3,712 (14) 
Other 8,570 (44) 1,386 (42) 9,956 (44) 1,214 (36) 254 (31) 1,468 (35) 9,784 (43) 1,640 (40) 11,424 (42) 
Not reported 53 (<1) 18 (<1) 71 (<1) 22 (<1) 1 (<1) 23 (<1) 75 (<1) 19 (<1) 94 (<1) 
ARIA+, Accessibility/Remoteness Index of Australia; ATSI, Aboriginal or Torres Strait Islander; BMI, body mass index; CVC, central venous catheter; EPO, erythropoietin; ESKD, end stage kidney disease; HD, 
haemodialysis; HDF, haemodiafiltration; MPI, Maori or Pacific Islander; RRT, renal replacement therapy; SEIFA, Socio-Economic Index For Australia.
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Table 2: Dialysis characteristics following 12 months of stabilisation of 18,972 incident patients commencing haemodiafiltration or standard haemodialysis between 1 January 2000 and 31 December 
2014. 
  Australia New Zealand Overall 
  HD HDF Total HD HDF Total HD HDF Total 
Total 15,242 985 16,227 2,455 290 2,745 17,697 1,275 18,972 
Last vascular access    
Native 12,164 (80) 816 (83) 12,980 (80) 1,806 (74) 173 (60) 1,979 (72) 13,970 (79) 989 (78) 14,959 (79) 
Synthetic 1,289 (8) 67 (7) 1,356 (8) 127 (5) 8 (3) 135 (5) 1,416 (8) 75 (6) 1,491 (8) 
Central venous catheter 1,789 (12) 102 (10) 1,891 (12) 522 (21) 109 (38) 631 (23) 2,311 (13) 211 (17) 2,522 (13) 
Blood flow rate    
<250 mL/min 562 (4) 17 (2) 579 (4) 188 (8) 9 (3) 197 (7) 750 (4) 26 (2) 776 (4) 
250-299 mL/min 2,433 (16) 103 (10) 2,536 (16) 598 (24) 82 (28) 680 (25) 3,031 (17) 185 (15) 3,216 (17) 
300-349 mL/min 8,849 (58) 564 (57) 9,413 (58) 1,186 (48) 169 (58) 1,355 (49) 10,035 (57) 733 (57) 10,768 (57) 
350+ mL/min 3,398 (22) 301 (31) 3,699 (23) 483 (20) 30 (10) 513 (19) 3,881 (22) 331 (26) 4,212 (22) 
Haemodialyser type    
Low flux 4,378 (29) 8 (<1) 4,386 (27) 1,438 (59) 0 (0) 1,438 (52) 5,816 (33) 8 (<1) 5,824 (31) 
High flux 10,863 (71) 977 (99) 11,840 (73) 1,017 (41) 290 (100) 1,307 (48) 11,880 (67) 1,267 (99) 13,147 (69) 
Not reported 1 (<1) 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 1 (<1) 
Treatment time (per session)    
<3 hours 71 (<1) 6 (<1) 77 (<1) 2 (<1) 0 (0) 2 (<1) 73 (<1) 6 (<1) 79 (<1) 
3-3.9 hours 892 (6) 57 (6) 949 (6) 82 (3) 8 (3) 90 (3) 974 (6) 65 (5) 1,039 (5) 
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4-4.9 hours 9,497 (62) 608 (62) 10,105 (62) 1,303 (53) 236 (81) 1,539 (56) 10,800 (61) 844 (66) 11,644 (61) 
5+ hours 4,781 (31) 314 (32) 5,095 (31) 1,068 (44) 46 (16) 1,114 (41) 5,849 (33) 360 (28) 6,209 (33) 
Not reported 1 (<1) 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 1 (<1) 
Frequency    
<3 per week 370 (2) 22 (2) 392 (2) 35 (1) 3 (1) 38 (1) 405 (2) 25 (2) 430 (2) 
3-3.4 per week 13,898 (91) 938 (95) 14,836 (91) 2,170 (88) 284 (98) 2,454 (89) 16,068 (91) 1,222 (96) 17,290 (91) 
3.5-3.9 per week 403 (3) 1 (<1) 404 (2) 102 (4) 0 (0) 102 (4) 505 (3) 1 (<1) 506 (3) 
4+ per week 570 (4) 24 (2) 594 (4) 148 (6) 3 (1) 151 (6) 718 (4) 27 (2) 745 (4) 
Not reported 1 (<1) 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 1 (<1) 
Estimated minimum convection volume 1    
<17 L - 588 (60) - - 238 (82) - - 826 (65) - 
17-19 L - 261 (26) - - 31 (11) - - 292 (23) - 
20-22 L - 92 (9) - - 9 (3) - - 101 (8) - 
22+ L - 44 (4) - - 12 (4) - - 56 (4) - 
Phosphate    
<1.6 mmol/L 7,222 (47) 477 (48) 7,699 (47) 817 (33) 113 (39) 930 (34) 8,039 (45) 590 (46) 8,629 (45) 
1.6+ mmol/L 7,115 (47) 500 (51) 7,615 (47) 1,494 (61) 177 (61) 1,671 (61) 8,609 (49) 677 (53) 9,286 (49) 
Not reported 905 (6) 8 (<1) 913 (6) 144 (6) 0 (0) 144 (5) 1,049 (6) 8 (<1) 1,057 (6) 
Haemoglobin    
<100 g/L 2,106 (14) 121 (12) 2,227 (14) 506 (21) 62 (21) 568 (21) 2,612 (15) 183 (14) 2,795 (15) 
100-119 g/L 7,401 (49) 528 (54) 7,929 (49) 1,122 (46) 157 (54) 1,279 (47) 8,523 (48) 685 (54) 9,208 (49) 
31 
 
120+ g/L 5,682 (37) 336 (34) 6,018 (37) 822 (33) 71 (24) 893 (33) 6,504 (37) 407 (32) 6,911 (36) 
Not reported 53 (<1) 0 (0) 53 (<1) 5 (<1) 0 (0) 5 (<1) 58 (<1) 0 (0) 58 (<1) 
Erythropoietin use    
Yes 3,025 (20) 160 (16) 3,185 (20) 706 (29) 42 (14) 748 (27) 3,731 (21) 202 (16) 3,933 (21) 
No 12,217 (80) 825 (84) 13,042 (80) 1,749 (71) 248 (86) 1,997 (73) 13,966 (79) 1,073 (84) 15,039 (79) 
HD, haemodialysis; HDF, haemodiafiltration; 1 For HDF patients only, calculated using the formula: blood flow rate (L/min) × treatment time per session (min) × 0.20 (minimum filtration fraction).
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Table 3: Multivariable Cox regression analysis of survival in 26 961 patients who commenced 
haemodialysis in Australia and New Zealand between 2000 and 2014. 
Covariates 
Australia New Zealand 
HR 95% CI P-value HR 95% CI P-value 
Haemodiafiltration 
  
<0.001 
  
0.05 
No 1.00 - 
 
1.00 - 
 Yes 0.79 0.72 - 0.87 
 
0.88 0.78 - 1.00 
 Age 
  
<0.001 
  
<0.001 
18-39 1.00 - 
 
1.00 - 
 40-54 1.49 1.29 - 1.72 
 
1.11 0.96 - 1.28 
 55-69 1.87 1.64 - 2.14 
 
1.51 1.23 - 1.84 
 70+ 2.75 2.38 - 3.18 
 
2.15 1.74 - 2.67 
 Sex 
  
<0.001 
  
<0.001 
Female 1.00 - 
 
1.00 - 
 Male 1.14 1.08 - 1.19 
 
1.19 1.15 - 1.23 
 Race 
  
<0.001 
  
<0.001 
White 1.00 - 
 
1.00 - 
 Aboriginal or Torres Strait Islander 1.04 0.91 - 1.20 
 
- - 
 Maori or Pacific Islander 0.73 0.64 - 0.84 
 
0.97 0.85 - 1.11 
 Asian or Indian 0.63 0.59 - 0.68 
 
0.74 0.67 - 0.82 
 Other 0.69 0.57 - 0.83 
 
0.86 0.65 - 1.13 
 BMI 
  
<0.001 
  
0.004 
0-18.4 (Underweight) 1.44 1.27 - 1.63 
 
1.39 1.02 - 1.90 
 18.5-29.9 (Normal-Overweight) 1.00 - 
 
1.00 - 
 30+ (Obese-Extremely Obese) 0.88 0.83 - 0.93 
 
1.07 1.00 - 1.14 
 Vascular access 
  
<0.001 
  
<0.001 
Native 1.00 - 
 
1.00 - 
 Synthetic 1.12 1.04 - 1.21 
 
1.07 0.90 - 1.26 
 Tunneled CVC 1.89 1.75 - 2.03 
 
1.67 1.48 - 1.87 
 
33 
 
Covariates 
Australia New Zealand 
HR 95% CI P-value HR 95% CI P-value 
Temporary CVC 2.18 1.82 - 2.61 
 
1.99 1.59 - 2.49 
 ESKD start 
  
<0.001 
  
0.1 
2000-2004 1.00 - 
 
1.00 - 
 2005-2009 0.92 0.86 - 0.97 
 
0.94 0.88 - 1.00 
 2010-2014 0.87 0.80 - 0.94 
 
0.92 0.73 - 1.15 
 Chronic lung disease 
  
<0.001 
  
<0.001 
No 1.00 - 
 
1.00 - 
 Yes 1.27 1.21 - 1.32 
 
1.22 1.09 - 1.37 
 Coronary artery disease 
  
<0.001 
  
<0.001 
No 1.00 - 
 
1.00 - 
 Yes 1.30 1.23 - 1.37 
 
1.58 1.47 - 1.71 
 Cerebrovascular disease 
  
<0.001 
  
0.01 
No 1.00 - 
 
1.00 - 
 Yes 1.27 1.20 - 1.33 
 
1.16 1.03 - 1.31 
 Peripheral vascular disease 
  
<0.001 
  
<0.001 
No 1.00 - 
 
1.00 - 
 Yes 1.25 1.18 - 1.31 
 
1.26 1.11 - 1.42 
 Diabetes (any type) 
  
<0.001 
  
0.004 
No 1.00 - 
 
1.00 - 
 Yes 1.26 1.19 - 1.33 
 
1.15 1.05 - 1.27 
 Smoking status 
  
0.01 
  
0.001 
Never smoked 1.00 - 
 
1.00 - 
 Current/former 1.06 1.01 - 1.11 
 
1.17 1.07 - 1.28 
 Previous transplant 
  
<0.001 
  
<0.001 
No 1.00 - 
 
1.00 - 
 Yes 0.47 0.39 - 0.56 
 
0.38 0.27 - 0.54 
 Initial treatment with HD 
  
0.8 
  
0.04 
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Covariates 
Australia New Zealand 
HR 95% CI P-value HR 95% CI P-value 
No 1.00 - 
 
1.00 - 
 Yes 0.99 0.93 - 1.06 
 
0.88 0.78 - 1.00 
 Blood flow rate 
  
<0.001 
  
<0.001 
Less than 250ml/min 1.00 - 
 
1.00 - 
 250-299ml/min 0.89 0.76 - 1.04 
 
0.65 0.51 - 0.81 
 300-349ml/min 0.75 0.61 - 0.91 
 
0.54 0.44 - 0.66 
 350ml/min or more 0.65 0.53 - 0.79 
 
0.59 0.46 - 0.75 
 Treatment time 
  
<0.001 
  
<0.001 
Each additional hour per week 0.93 0.92 - 0.94 
 
0.95 0.93 - 0.97 
 Dialysis location 
  
<0.001 
  
<0.001 
Home 0.56 0.48 - 0.65 
 
0.57 0.46 - 0.71 
 Hospital 1.00 - 
 
1.00 - 
 Satellite 0.64 0.59 - 0.70   0.61 0.50 - 0.74   
1 For the New Zealand analysis, Aboriginal and Torres Strait Islander was categorized as Other. ATSI, Aboriginal or Torres 
Strait Islander; BMI, body mass index; CVC, central venous catheter; haemodialysis, haemodialysis; haemodiafiltration, 
haemodiafiltration; MPI, Maori or Pacific Islander; RRT, renal replacement therapy; SEIFA, Socio-Economic Index For 
Australia. 
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Table 4: Multivariable Cox regression model comparing all-cause mortality and multivariable cause-specific regression models 
comparing cardiovascular and non-cardiovascular mortality for an overall effect of haemodiafiltration compared to a difference in 
effect between the first 12 months of haemodialysis and subsequent years 
Country Outcome Overall effect  Haemodiafiltration effect over time 
  HR (95%CI) P-value  First 12 months 
HR (95%CI) 
More than one year 
HR (95%CI) 
P-value for 
change over time 
Australia All-cause mortality 0.79 (0.72, 0.87) <0.001  0.55 (0.35, 0.87) 0.81 (0.74, 0.89) 0.09 
Australia Cardiovascular mortality 0.79 (0.65, 0.96) 0.01  0.71 (0.38, 1.34) 0.80 (0.66, 0.96) 0.76 
Australia Non-cardiovascular mortality 0.80 (0.73, 0.88) <0.001  0.74 (0.56, 0.99) 0.82 (0.74, 0.90) 0.53 
        
New Zealand All-cause mortality 0.88 (0.78, 1.00) 0.05  0.67 (0.54, 0.83) 0.90 (0.79, 1.03) 0.01 
New Zealand Cardiovascular mortality 1.09 (0.85, 1.41) 0.48  0.59 (0.38, 0.91) 1.21 (0.91, 1.60) 0.002 
New Zealand Non-cardiovascular mortality 0.77 (0.70, 0.86) <0.001  0.56 (0.45, 0.70) 0.82 (0.72, 0.94) 0.007 
36 
 
 
FIGURE LEGENDS 
Figure 1 Inception cohort patients included in analysis. 
Figure 2 Modelled survival curves comparing patient survival between 4110 patients 
managed with haemodiafiltration and 22 851 patients managed with haemodialysis by 
country. The difference between the groups was statistically significant for Australia 
(p<0.001) and New Zealand (p<0.001). 
Figure 3 Multivariable Cox regression model comparing all-cause mortality and 
multivariable cause-specific regression models comparing cardiovascular and non-
cardiovascular mortality between 4110 patients managed with haemodiafiltration and 22 851 
patients managed with standard haemodialysis by country. 
Figure 4 Multivariable cause-specific regression models comparing cardiovascular and non-
cardiovascular mortality between 4110 patients managed with haemodiafiltration and 22 851 
patients managed with standard haemodialysis by country. 
Figure 5 Multivariable Cox regression model comparing all-cause mortality by patient 
subgroup in 4110 patients managed with haemodiafiltration and 22 851 patients managed 
with standard haemodialysis by country. 
Figure 6 Multivariable Cox regression model comparing cardiovascular mortality by patient 
subgroup in 4110 patients managed with haemodiafiltration and 22 851 patients managed 
with standard haemodialysis by country. 
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Figure 1. Inception cohort patients included in analysis. 
 
  
Patients included in analysis 
26,961 (97%) 
New Zealand patients 
Total 4,187 (15%) 
Haemodiafiltration 808 
Standard haemodialysis 3,379 
Adult patients who initiated 
haemodialysis between 2000-
2014, and completed at least 
one end-of-year survey 
27,702 (100%) 
Incomplete records 
Total 741 (3%) 
Missing dialysis type 269 (<1%) 
Missing one or more covariates, 472 (2%) 
Australian patients 
Total 22,774 (82%) 
Haemodiafiltration 3,302 
Standard haemodialysis 19,472 
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Figure 2. Modelled survival curves comparing patient survival between 4110 patients 
managed with haemodiafiltration and 22851 patients managed with haemodialysis by 
country. The difference between the groups was statistically significant for Australia 
(p<0.001) and New Zealand (p<0.001). 
 
 
A: Australia 
 
B: New Zealand  
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Figure 3. Multivariable Cox regression model comparing all-cause mortality and 
multivariable cause-specific regression models comparing cardiovascular and non-
cardiovascular mortality between 4110 patients managed with haemodiafiltration and 
22 851 patients managed with standard haemodialysis by country. 
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Figure 4. Cause-specific survival curves comparing cardiovascular and non-
cardiovascular mortality between 4110 patients managed with haemodiafiltration and 
22 851 patients managed with standard haemodialysis by country. 
 
A: Australia 
 
B: New Zealand 
41 
 
Figure 5. Multivariable Cox regression model comparing all-cause mortality by patient 
subgroup in 4110 patients managed with haemodiafiltration and 22 851 patients 
managed with standard haemodialysis by country. 
 
Estimates shown include hazard ratio with 95% confidence intervals. P-value for interaction reports significant differences 
between subgroups and the outcome of interest. 
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Figure 6. Multivariable Cox regression model comparing cardiovascular mortality by 
patient subgroup in 4110 patients managed with haemodiafiltration and 22 851 patients 
managed with standard haemodialysis by country. 
 
Estimates shown include hazard ratio with 95% confidence intervals. P-value for interaction reports significant differences 
between subgroups and the outcome of interest. 
 
